Pinetree Therapeutics, Inc" has the MATESM platform technology to discover and develop a bispecific or multispecific antibody which potentially treats "so-called difficult-to-treat" solid cancers due to high mutation burden including undruggable genetic mutants. Our lead candidates are in the lead selection stage near the pre-clinical trial. Their unique dual inhibition leads to creating strong anti-tumor immunity via an increasing number and an improving function of cytotoxic CD8 T-cell via selectively inhibiting regulatory T cells only in the tumor, but not in the peripheral blood system. Also it yields a strong direct anti-tumor effect against lung adenocarcinoma cells with multiple (undruggable) oncogenic mutations including KRAS/NRAS, TP53, BRAC2, and others. Consequently, such dual inhibition likely leads to strong and combinatorial efficacy in the tumor microenvironment in several cancer types including lung and pancreatic cancer.